KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer

MLL3 histone methyltransferase, encoded by the KMT2C gene, is a tumor suppressor that has an essential role in cell‐type‐specific gene expression. We evaluated the prognostic significance of KMT2C promoter methylation as a circulating epigenetic biomarker in plasma cell‐free DNA (cfDNA) in non‐small...

Full description

Bibliographic Details
Main Authors:	Sofia Mastoraki, Ioanna Balgkouranidou, Emily Tsaroucha, Apostolos Klinakis, Vassilis Georgoulias, Evi Lianidou
Format:	Article
Language:	English
Published:	Wiley 2021-09-01
Series:	Molecular Oncology
Subjects:	cfDNA epigenetic biomarkers KMT2C liquid biopsy MLL3 NSCLC
Online Access:	https://doi.org/10.1002/1878-0261.12848

Similar Items

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
by: Doralina do Amaral Rabello, et al.
Published: (2018-02-01)

Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients
by: Elisabetta Zulato, et al.
Published: (2021-08-01)

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
by: Martyna Filipska, et al.
Published: (2021-06-01)

KMT2A and KMT2B Mediate Memory Function by Affecting Distinct Genomic Regions
by: Cemil Kerimoglu, et al.
Published: (2017-07-01)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
by: Riziero Esposito Abate, et al.
Published: (2020-12-01)

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
by: Vinh Thanh Tran, et al.
Published: (2020-08-01)

Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review
by: Adrian Martuszewski, et al.
Published: (2021-01-01)

Clinical and Neurobehavioral Features of Three Novel Kabuki Syndrome Patients with Mosaic KMT2D Mutations and a Review of Literature
by: Francesca Romana Lepri, et al.
Published: (2017-12-01)

<i>USP44</i> Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer
by: Dora Londra, et al.
Published: (2021-09-01)

Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer
by: Bor-Uei Shyr, et al.
Published: (2021-05-01)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
by: Laurence C. Cheung, et al.
Published: (2021-04-01)

Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer
by: Daniel Fernandez-Garcia, et al.
Published: (2019-12-01)

Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer
by: Morten Lapin, et al.
Published: (2018-11-01)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
by: Sadakatsu Ikeda, et al.
Published: (2018-06-01)

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review
by: Ian A. Cree, et al.
Published: (2017-10-01)

Bisulfite Amplicon Sequencing Can Detect Glia and Neuron Cell-Free DNA in Blood Plasma
by: Zac Chatterton, et al.
Published: (2021-07-01)

Advances in Prognostic Methylation Biomarkers for Prostate Cancer
by: Dilys Lam, et al.
Published: (2020-10-01)

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
by: Marta Sesé, et al.
Published: (2019-08-01)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
by: Bram De Laere, et al.
Published: (2021-03-01)

Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations
by: Amira Bouzidi, et al.
Published: (2021-08-01)

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer
by: Patricia Mondelo-Macía, et al.
Published: (2021-01-01)

Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
by: Silvia R. Vitale, et al.
Published: (2021-03-01)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
by: Christi M. J. Steendam, et al.
Published: (2020-10-01)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
by: José Manuel González de Aledo-Castillo, et al.
Published: (2021-07-01)

Critical Roles of the Histone Methyltransferase MLL4/KMT2D in Murine Hepatic Steatosis Directed by ABL1 and PPARγ2
by: Dae-Hwan Kim, et al.
Published: (2016-11-01)

Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms
by: Stefan Grabuschnig, et al.
Published: (2020-10-01)

Technological advances in free-circulating tumor-derived DNA methylation analysis
by: Marcin Skalski, et al.
Published: (2019-12-01)

DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?
by: Susana García-Silva, et al.
Published: (2021-01-01)

Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy
by: Kezhong Chen, et al.
Published: (2021-01-01)

Detection of mutational patterns in cell‐free DNA of colorectal cancer by custom amplicon sequencing
by: Simon Herrmann, et al.
Published: (2019-08-01)

Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity
by: Maxim Ivanov, et al.
Published: (2019-03-01)

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
by: Jeeyun Lee, et al.
Published: (2019-04-01)

Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers
by: Sohan Punia, et al.
Published: (2021-04-01)

Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females
by: Yu-Feng Huang, et al.
Published: (2018-02-01)

A new primer construction technique that effectively increases amplification of rare mutant templates in samples
by: Jr-Kai Huang, et al.
Published: (2019-08-01)

Comparing cell‐free circulating tumor DNA mutational profiles of disease‐free and nonresponders patients with oropharyngeal squamous cell carcinoma
by: Alok R. Khandelwal, et al.
Published: (2020-10-01)

KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation
by: Yang Fang, et al.
Published: (2019-07-01)

Concentrations of Plasma Nucleosomes but Not Cell-Free DNA Are Prognostic in Dogs Following Trauma
by: Jo-Annie Letendre, et al.
Published: (2018-07-01)

Liquid Biopsy in Thyroid Cancer: New Insight
by: Fatemeh Khatami, et al.
Published: (2018-07-01)